The FDA announced that it is working closely with other government agencies and academic centers to investigate the potential use of chloroquine for the treatment of coronavirus disease 2019 (COVID-19).
A phase 1 clinical trial evaluating an investigational vaccine for protection against coronavirus disease 2019 (COVID-19) has been initiated at the Kaiser Permanente Washington Health Research Institute (KPWHRI) in Seattle.
The FDA has approved Ofev (nintedanib; Boehringer Ingelheim) for the treatment of patients with chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype.
The FDA has accepted for review the Biologics License Application for tanezumab 2.5mg administered subcutaneously for moderate to severe osteoarthritis pain.
Avion Pharmaceuticals announced the launch of Gloperba (colchicine) oral solution for prophylaxis of gout flares in adults.
Positive topline data were announced from the phase 3 SELECT-PsA 1 study of upadacitinib, a Janus Kinase (JAK) inhibitor, in adult patients with active psoriatic arthritis who have had an inadequate response to at least 1 nonbiologic disease modifying antirheumatic drug (DMARD).
The FDA has granted Orphan Drug designation to TNP-2092 (TenNor Therapeutics) powder for intravenous IV injection for the treatment of prosthetic joint infections.
In addition to a panel of experts, for the first time, the guideline was developed with the help of patients, emphasizing the importance of shared decision-making.
GlaxoSmithKline announced positive results from the phase 3 BLISS-LN trial of belimumab for the treatment of active lupus nephritis in adult patients.
Gilead Sciences has submitted a New Drug Application to the FDA for priority review of filgotinib for the treatment of moderate to severe rheumatoid arthritis in adult patients.
